Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaluvu Balaraman

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
International Journal of Molecular Sciences|July 28, 2022
Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing MiceXiaoguang Liu, Kaluvu Balaraman, Ciarán C Lynch, et al.
European Journal of Medicinal Chemistry|March 14, 2023
Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viabilityKaluvu Balaraman, Emre Deniz, Eryn Nelson, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 15, 2015
In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous routeKaluvu Balaraman, Nashira Campos Vieira, Fathi Moussa, et al.
Experimental Parasitology|August 4, 2018
In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsionAndreza Rochelle do Vale Morais, André Leandro Silva, Sandrine Cojean, et al.
Human Molecular Genetics|August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Human Molecular Genetics|May 24, 2021
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
International Journal of Molecular Sciences|July 28, 2022
Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing MiceXiaoguang Liu, Kaluvu Balaraman, Ciarán C Lynch, et al.
European Journal of Medicinal Chemistry|March 14, 2023
Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viabilityKaluvu Balaraman, Emre Deniz, Eryn Nelson, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 15, 2015
In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous routeKaluvu Balaraman, Nashira Campos Vieira, Fathi Moussa, et al.
Experimental Parasitology|August 4, 2018
In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsionAndreza Rochelle do Vale Morais, André Leandro Silva, Sandrine Cojean, et al.
Human Molecular Genetics|August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Human Molecular Genetics|May 24, 2021
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Pageof 3